- Home
- GLMD vs ACXP Comparison
GLMD vs ACXP Comparison
Compare GLMD & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- ACXP
- Stock Information
- Founded
- GLMD 2000
- ACXP 2017
- Country
- GLMD Israel
- ACXP United States
- Employees
- GLMD N/A
- ACXP N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- ACXP Health Care
- Exchange
- GLMD Nasdaq
- ACXP Nasdaq
- Market Cap
- GLMD 7.5M
- ACXP 6.8M
- IPO Year
- GLMD 2014
- ACXP 2021
- Fundamental
- Price
- GLMD $1.48
- ACXP $4.23
- Analyst Decision
- GLMD Hold
- ACXP Strong Buy
- Analyst Count
- GLMD 1
- ACXP 3
- Target Price
- GLMD N/A
- ACXP $143.67
- AVG Volume (30 Days)
- GLMD 213.6K
- ACXP 68.2K
- Earning Date
- GLMD 11-13-2025
- ACXP 11-12-2025
- Dividend Yield
- GLMD N/A
- ACXP N/A
- EPS Growth
- GLMD N/A
- ACXP N/A
- EPS
- GLMD N/A
- ACXP N/A
- Revenue
- GLMD N/A
- ACXP N/A
- Revenue This Year
- GLMD N/A
- ACXP N/A
- Revenue Next Year
- GLMD N/A
- ACXP N/A
- P/E Ratio
- GLMD N/A
- ACXP N/A
- Revenue Growth
- GLMD N/A
- ACXP N/A
- 52 Week Low
- GLMD $1.15
- ACXP $3.80
- 52 Week High
- GLMD $23.80
- ACXP $44.00
- Technical
- Relative Strength Index (RSI)
- GLMD 51.13
- ACXP 48.38
- Support Level
- GLMD $1.33
- ACXP N/A
- Resistance Level
- GLMD $1.60
- ACXP $4.34
- Average True Range (ATR)
- GLMD 0.10
- ACXP 0.45
- MACD
- GLMD 0.03
- ACXP -0.05
- Stochastic Oscillator
- GLMD 66.67
- ACXP 59.16
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.